GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » 5-Year Yield-on-Cost %

JW (Cayman) Therapeutics Co (HKSE:02126) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co 5-Year Yield-on-Cost %?

JW (Cayman) Therapeutics Co's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for JW (Cayman) Therapeutics Co's 5-Year Yield-on-Cost % or its related term are showing as below:



HKSE:02126's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.76
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of JW (Cayman) Therapeutics Co's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW (Cayman) Therapeutics Co's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's 5-Year Yield-on-Cost % falls into.



JW (Cayman) Therapeutics Co 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of JW (Cayman) Therapeutics Co is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

JW (Cayman) Therapeutics Co  (HKSE:02126) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


JW (Cayman) Therapeutics Co 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Traded in Other Exchanges
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Executives
Li Dan 2202 Interest of your spouse
Li Yiping James 2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd. 2501 Other
Bristol-myers Squibb Company 2201 Interest of corporation controlled by you
Celgene Corporation 2201 Interest of corporation controlled by you
Juno Therapeutics, Inc. 2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd. 2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines